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Abstract. Papillary thyroid carcinoma (PTC) and medullary 
thyroid carcinoma (MTC) are characterized by genomic rear-
rangements and point mutations in the proto-oncogene RET. 
Leucine-rich repeats and immunoglobulin-like domains 1 
(LRIG1) is a suppressor of various receptor tyrosine kinases, 
including RET. LRIG1 expression levels are associated 
with patient survival in many cancer types. In the present 
study, we investigated whether the oncogenic RET mutants 
RET2A (C634R) and RET2B (M918T) were regulated by 
LRIG1, and the possible effects of LRIG1 expression in thyroid 
cancer were investigated in three different clinical cohorts and 
in a RET2B-driven mouse model of MTC. LRIG1 was shown 
to physically interact with both RET2A and RET2B and to 
restrict their ligand-independent activation. LRIG1 mRNA 
levels were downregulated in PTC and MTC compared to 
normal thyroid gland tissue. There was no apparent asso-
ciation between LRIG1 RNA or protein expression levels 
and patient survival in the studied cohorts. The transgenic 
RET2B mice developed pre-cancerous medullary thyroid 
lesions at a high frequency (36%); however, no overt cancers 
were observed. There was no significant difference in the inci-
dence of pre-cancerous lesions between Lrig1 wild-type and 
Lrig1-deficient RET2B mice. In conclusion, the findings that 
LRIG1 is a negative regulator of RET2A and RET2B and is 
also downregulated in PTC and MTC may suggest that LRIG1 
functions as a thyroid tumor suppressor.
Introduction
Thyroid carcinoma is the most common endocrine malig-
nancy. In 2008, ~212,000 new cases were diagnosed 
worldwide (1). Thyroid carcinomas are classified into three 
major morphological well-differentiated types: papillary 
thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) 
and medullary thyroid carcinoma (MTC) with overall good 
prognosis (2). In contrast, poorly differentiated thyroid 
carcinoma (PDTC) and undifferentiated anaplastic thyroid 
carcinoma (ATC) carry a poor prognosis (2). PTC, FTC, PDTC 
and ATC are believed to originate from follicular cells, whereas 
MTC is believed to be derived from calcitonin-producing 
parafollicular cells (also called C-cells). Multiple endocrine 
neoplasia type 2A (MEN2A) and 2B (MEN2B) are caused by 
germ-line mutations in the proto-oncogene rearranged during 
transfection (RET) and are also associated with an increased 
incidence of MTC (3). The most common RET mutations in 
MEN2A and MEN2B are C634R and M918T, respectively (4) 
(hereafter the correspondingly mutated receptors are referred 
to as RET2A and RET2B, respectively). Twenty-five to 30% of 
MTC cases are associated with heritable RET mutations (5). In 
sporadic MTC, somatic RET mutations, typically the M918T 
mutation, are present in ~50% of cases (3). In PTC, genomic 
rearrangements involving RET and different partner genes are 
common, especially in radiation-induced cases (reviewed in 
ref. 5). Thus, the incidence of RET rearrangements in PTC 
ranges from 87%, in a series of early cases from the Chornobyl 
nuclear accident (6), to 20 and 7%, in two recent series of 
sporadic cases (3,7,8). In most cases, thyroid carcinomas are 
localized to the thyroid gland and the treatment used for these 
patients includes surgery, radiation therapy and radioiodine 
therapy. For patients with metastatic disease, however, the 
treatment options are limited.
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The human leucine-rich repeats and immunoglobulin-like 
domains (LRIG) gene family includes three genes: LRIG1, 
LRIG2 and LRIG3 (9-11). Increasing evidence indicates 
that LRIG1 functions as a tumor suppressor (reviewed in 
refs. 12 and 13) and the high expression of the LRIG1 mRNA 
or protein are associated with an increased survival in breast 
cancer (14), ovarian cancer (15), uterine cervical cancer (16), 
cutaneous squamous cell carcinoma (17), nasopharyngeal 
and oropharyngeal cancer (18,19), non-small cell lung 
cancer (20), and hepatocellular carcinoma (21). Molecular 
studies have shown that LRIG1 negatively regulates wild-
type tyrosine kinase receptors of the epidermal growth factor 
receptor (EGFR) family (22-25), hepatocyte growth factor 
receptor (MET) (26), RET (27), platelet-derived growth 
factor receptor α (PDGFRA) (28), and neurotrophic tyrosine 
kinase receptor type 2 (NTRK2, also known as TRKB) (29). 
However, it is not known whether the MEN2- and thyroid 
cancer-associated mutant RET receptors, RET2A and RET2B, 
are also LRIG1 targets.
The aim of the present study was to investigate the possible 
role of LRIG1 in thyroid carcinoma. We investigated whether 
LRIG1 regulates RET2A and RET2B at the molecular level, 
analyzed the expression and possible prognostic value of 
LRIG1 in three human thyroid carcinoma cohorts, and inves-
tigated the role of Lrig1 in a transgenic RET2B-driven mouse 
MTC model.
Materials and methods
Cell culture, plasmids and transfections. COS-7 cells (ATCC, 
Manassas, VA, USA) were grown in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal bovine serum, 
as previously described (29). The cells were transiently 
transfected with polyethylenimine-PEI (Polysciences, Inc., 
Warrington, PA, USA). Plasmid cDNA encoding full-length, 
Flag-tagged LRIG1 has been described previously (30). The 
expression vector encoding RET2A (C634R) was previously 
described (31). The cDNA expression vector encoding RET2B 
(M918T) was kindly provided by Dr M. Santoro at University 
Federico II (Naples, Italy) (32).
Immunoprecipitations and western blotting. The cells were 
lysed at 4˚C in TNE-buffer (50 mM Tris pH 7.5, 150 mM NaCl 
and 2 mM EDTA) supplemented with 0.5% Triton X-100, 
1% octyl-β-glucoside, phosphatase inhibitors (50 mM NaF, 
2 mM Na3VO4), and complete EDTA-free protease inhibitors 
(Roche). Cell lysates were clarified by centrifugation and 
analyzed by immunoprecipitation and western blotting using 
previously described methodologies (27). Ligand-independent 
RET phosphorylation was examined at 48 h after transfec-
tion in COS-7 cells expressing RET2A or RET2B constructs 
together with either an empty vector or Flag-LRIG1. The blots 
were scanned in a Storm 845 PhosphorImager and quantifica-
tions were conducted with ImageQuant software (both from 
GE Healthcare Life Sciences, Capital Federal, Argentina). The 
antibodies used were anti-phosphotyrosine (p-Tyr, clone PY99, 
catalogue no. SC7020) at a 1:10,000 dilution, anti-Ret (goat 
antibodies C20 and T20, catalogue no. SC-1290) (both from 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a 1:1,000 
dilution, and anti-Flag M2 mouse monoclonal antibody 
(catalogue no. F1804; Sigma-Aldrich, St. Louis, MO, USA) at 
a 1:1,500 dilution.
Patient cohorts. Three different patient cohorts were investi-
gated. The first cohort (Cohort1-TCGA) comprised the thyroid 
carcinoma cases available at The Cancer Genome Atlas 
(TCGA), which included 502 PTC and 58 normal thyroid gland 
tissues (http://cancergenome.nih.gov/; December 15, 2016). The 
RNAseq count data and patient survival data were downloaded 
from TCGA (http://cancergenome.nih.gov/; December 15, 
2016). The samples were upper quartile normalized FPKM 
(UQ-FPKM) and the samples were log-transformed to follow 
a normal distribution.
The second cohort (Cohort2-MTC) has been described 
previously (33) and included 39 MTC patient samples and 
12 normal tissue controls collected with informed consent and 
local ethical approval at the Karolinska University Hospital. 
The clinical data, survival and mutation status of the RET and 
RAS genes were as reported in a previous study (33).
The third cohort (Cohort3-TMA) was collected with the 
aim of including all patients diagnosed with thyroid carcinoma 
in the county of Dalarna, Sweden, between the years 1980 and 
2008. The study was approved by the Regional Ethics Review 
Board in Uppsala (dnr 2010/351), and the Swedish Cancer 
Registry was used to identify the patients. Only patients who 
provided written informed consent were included in the study. 
Paraformaldehyde-fixed and paraffin-embedded tissues were 
retrieved from hospital archives and used to assemble a tissue 
microarray (TMA). The diagnostic groups PTC, FTC, MTC, 
PDTC and ATC were represented, and FTCs with or without 
oncocytic features (so called Hurthle cell or oxyphilic) were 
separately studied. All patients gave written informed consent 
prior to their inclusion in the study. The clinical data were 
collected from patient files, including histology, TNM stage, 
time to relapse, and date and cause of death.
RNA extraction and quantitative real-time RT-PCR. The 
RNA from Cohort2-MTC, which had been prepared previ-
ously (33), was treated with TURBO DNA-free kit (Life 
Technologies) according to the manufacturer's instructions. 
Human LRIG1 and the reference gene RN18S were analyzed 
in triplicate samples of 20 ng total RNA through quantitative 
reverse transcription (RT) polymerase chain reaction (PCR), 
essentially as previously described (9). However, in contrast 
to what was previously described (9), qScript 1-Step qRT-PCR 
Kit (Quanta Biosciences, Gaithersburg, MD, USA) and a 
Bio-Rad CFX96 apparatus (Bio-Rad Laboratories AB) were 
used. The RN18S-normalized LRIG1 levels were divided 
by the corresponding level in the QPCR Human Reference 
Total RNA (Agilent Technologies, Santa Clara, CA, USA). 
Thus, the normalized LRIG1 level in the reference RNA was 
set to the value of 1.
Antibodies and evaluation of immunohistochemistry. Immuno-
histochemistry (IHC) was performed for Cohort3-TMA. IHC 
was performed on 4-µm TMA sections using the LRIG1-151 
antibody (18,30) at a dilution of 1:50. The antibody against 
human LRIG1 has been previously described. The intensity 
and proportion of positive cells were evaluated by an expe-
rienced pathologist (M.T.), who had previously performed a 
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similar evaluation using the same semi-quantitative evaluation 
scale in another material (18). Briefly, the intensity was evalu-
ated as absent (0), weak (1+), intermediate (2+), or strong (3+), 
and the fraction of positive cells were evaluated and scored as 
0%, 1-25%, 26-50%, 51-75% or 76-100% positive cells.
Animal experiments. All mice were housed and maintained, and 
all experiments were performed in accordance with the European 
Communities Council Directive (86/609/EEC). The experi-
mental protocols were approved by the Regional Ethics 
Committee of Umeå University in Umeå, Sweden (registration 
nos. A80-08 and A81-11). The animals were housed under 
controlled conditions with a 12-h day/night cycle and fed water 
and standard chow pellets (cat. no. 801730; Special Diets 
Services, NOVA-SCB Sweden, Sollentuna, Sweden) ad libitum. 
The Lrig1-deficient allele has been described previously (34) and 
was bred onto a pure C57BL/6J genetic background for five 
generations. Heterozygous Lrig1 mice were crossed with a trans-
genic mouse strain that ectopically expresses the human RET2B 
oncogene under the human calcitonin promoter and develop 
MTC at a high frequency (35,36). The RET2B mice were of a 
mixed genetic background (C57BL/6J:DBA2, 1:1). The mouse 
genotypes were determined using tail DNA, PCR, and standard 
molecular biology techniques. The PCR primers that were used 
for the Lrig1 wild-type were: 5'-GCGAGCGTGTGTTGTGG 
AGAGGAT-3' and 5'-CGATTGTCTGGTGATCAGGAGAC 
TGC-3', those used for the Lrig1 knockout were: 5'-ACCTCA 
GGGAGCGAGCGCTCTTATGGGTTAGGACG-3' and 5'-CCC 
GTGATATTGCTGAAGAGCTTGGCGGCGAATGG-3', and 
those used for the RET2B were: 5'-TGGAGACCCAAGACATC 
AAC-3' and 5'-GGAGAAGAGGACAGCGGCT-3'. The PCR 
products (405 bp for the Lrig1 wild-type; 1,060 bp for the Lrig1 
knockout; and 220 bp for the RET2B) were separated and visual-
ized using analytical agarose gel electrophoresis.
The plasma calcitonin levels of the mice were measured 
every third month according to the methodology as previously 
described (36). Plasma calcitonin is an established marker of 
MTC and increased levels of it are usually detectable long 
before general signs of the disease. At 2 years of age or at signs 
of the disease, the mice were sacrificed and their thyroid glands 
were dissected, fixed in 4% phosphate-buffered formaldehyde, 
embedded in paraffin, and stained with routine hematoxylin 
and eosin staining.
Statistical analyses. To analyze differential gene expression, 
the tumor samples were compared with normal samples using 
a Student's t-test in Cohort1-TCGA and a Mann-Whitney U test 
in Cohort2-MTC. Associations between ordinal variables 
were tested using the Wilcoxon rank sum test, χ2 test, one-way 
analysis of variance (ANOVA) not assuming equal vari-
ances, or Fisher's exact test, where appropriate. For survival 
analysis, the tumor samples were divided into two groups 
of high and low LRIG1, with the median as the cut-off, and 
the cumulative survival was then analyzed in the two groups 
and compared using the log-rank test. Survival was assessed 
in a Kaplan-Meier graph and a log-rank test was used for 
comparing different groups. Progression-free survival (PFS, 
the end-point date of relapse, censoring at the date of the last 
follow-up), disease-specific survival (DSS, the end-point date 
of death when thyroid cancer was specified as the cause of 
death, censoring at the date of the last follow-up), and overall 
survival (OS, the end-point date of death from any cause, 
censoring at the date of the last follow-up) were all addressed. 
The groups that were investigated included the expression of 
LRIG1, as well as other known prognostic factors, including 
clinical stage and age. All of the significance testing was 
performed at the 0.05 level and only two-sided P-values were 
presented.
Results
Interactions between LRIG1 and mutant RET2A and RET2B 
proteins. To investigate whether LRIG1 interacts with and 
regulates the oncogenic RET2A and RET2B receptors, 
COS-7 cells were co-transfected with LRIG1 and the respec-
tive RET variant. After 48 h, cell lysates were prepared and 
subjected to immunoprecipitation and western blot analysis. 
LRIG1 physically interacted with both RET2A and RET2B, 
as shown by the co-immunoprecipitation of LRIG1 and the 
RET2A and RET2B proteins (Fig. 1A and B). Furthermore, 
LRIG1 co-expression induced the downregulation of the phos-
phorylation levels of RET2A and RET2B without significantly 
affecting the corresponding total protein levels (Fig. 1C-F). 
Thus, LRIG1 physically interacted with and inhibited the 
activation of both RET2A and RET2B.
LRIG1 gene and protein expression levels and comparison 
to clinical features. To investigate the importance of LRIG1 
expression in thyroid cancer, we i) analyzed the PTC expres-
sion data available at TCGA (Cohort1-TCGA), ii) performed 
quantitative RT-PCR analysis of a series of MTC samples 
(Cohort2-MTC), and iii) analyzed a thyroid cancer TMA 
(Cohort3-TMA) through immunohistochemistry.
Cohort1-TCGA contained data from 502 PTC samples 
and 58 normal thyroid gland samples. In this material, the 
mean LRIG1 expression level was lower in PTC than in the 
normal thyroid gland (P=2.2x10-16, Student's t-test) (Fig. 2A). 
There was a significant association between a higher PTC 
clinical stage and lower LRIG1 expression (P=0.0034, one-way 
ANOVA) (Fig. 2B). There was no significant association 
between the OS of patients and the LRIG1 expression level in 
the TCGA data set (high versus low LRIG1 expression level, 
median used as cut-off; P=0.435, log-rank test).
In Cohort2-MTC, the relative LRIG1 mRNA levels were 
analyzed in 39 MTC and 12 normal thyroid glands through 
quantitative RT-PCR. Twenty-two of the 39 (56%) MTC cases 
were RET mutated, whereas six (15%) showed either HRAS 
or KRAS mutations (33). The intragroup variability of LRIG1 
expression was relatively high, as evidenced from the sample 
standard deviations from the means that were 179 and 70% for 
the normal and MTC samples, respectively. Nevertheless, the 
relative LRIG1 expression level was significantly lower in MTC 
than in normal thyroid gland (0.38, SD ±0.27 vs. 1.94, SD ±3.47; 
P=0.00063, Mann-Whitney U test) (Fig. 2C). Both the RET 
mutated and RET wild-type cases showed significantly lower 
LRIG1 levels than the normal thyroid glands (0.41, SD ±0.33 
and 0.34, SD ±0.15, respectively vs. 1.94, SD ±3.47; P=0.0036 
and P=0.0016, respectively). There was a statistically insignifi-
cant association between a higher MTC clinical stage and lower 
LRIG1 expression (P=0.136, Kruskal-Wallis test) (Fig. 2D). 
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There was no significant difference in LRIG1 levels between 
the RET-mutated, RAS-mutated, or other MTCs.
Cohort3-TMA was analyzed by immunohistochem-
istry (IHC) using a TMA with 118 thyroid carcinomas (Table I). 
In this cohort, 125 patients gave informed consent to partici-
pate (Table I) and it was possible to perform IHC on samples 
from 118 patients, whereas for 7 patients, it was not possible 
to perform this analysis because of the limited amount of 
available tissue. Examples of cases with different LRIG1 
staining intensities and proportions of positive cells are shown 
in Fig. 3. Detailed data on the clinical parameters and results of 
IHC for Cohort3-TMA are presented in Table I. The possible 
associations between LRIG1 immunoreactivity (proportion of 
positive cells or intensity of staining) and histology, clinical 
stage, age, sex, and clinical outcome were investigated. A 
significant difference was found when histology was compared 
with the percentage of LRIG1-positive cells (P=0.026, χ2 test) 
and intensity of LRIG1 staining (P=0.033, χ2 test). This showed 
that the distribution of LRIG1 immunoreactivities (percentage 
or intensity) was different between the different histological 
groups. However, because of the small sample sizes, it was not 
possible to draw firm conclusions about the distributions within 
individual groups. Both the fraction of LRIG1-positive cells and 
the intensity of LRIG1 staining were associated with whether 
Figure 1. LRIG1 interacts with and restricts the ligand-independent constitutive phosphorylation of RET2A and RET2B oncogenic mutants. A schematic 
representation of RET2A (i.e., C643R recurrent in MEN2A) and RET2B (i.e., M918T seen in MEN2B and sporadic MTC) are shown at the top. TKD 
indicates tyrosine-kinase domain and CRD indicates a cysteine-rich domain. (A and B) Co-immunoprecipitation between Flag-tagged LRIG1 (Flag-LRIG1) 
and RET2A (A) or RET2B (B) overexpressed in COS-7 cells. Cell extracts were analyzed by immunoprecipitation (IP) with anti-Flag antibodies followed by 
western blotting (WB) with antibodies against RET and reincubation of the same blots with the anti-Flag antibody. The bottom panels show the RET expres-
sion in cell lysates. Similar results were obtained in two independent assays. (C and D) Ligand-independent RET2A and RET2B tyrosine phosphorylation in 
COS-7 cells transfected with either the control vector or Flag-LRIG1. The total lysates were immunoprecipitated with anti-RET antibodies followed by WB 
with antibodies against phosphotyrosine (p-Tyr). The re-probing of the same blot with anti-RET antibodies is also shown. The bottom panels show the Flag-
LRIG1 expression in cell lysates. The numbers below the lanes indicate the fold of induction relative to the control and normalized to the total levels of RET 
protein. (E and F) Bar graphs showing the levels of ligand-independent RET2A (E) and RET2B (F) phosphorylation in the absence or presence of Flag-LRIG1, 
as assessed in (C and D). The results are shown as the mean ± SEM of n=5 (E) or n=3 (F) independent experiments. *P<0.05 by Student's t-test. MTC, medullary 
thyroid carcinoma; RET, rearranged during transfection; LRIG1, leucine-rich repeats and immunoglobulin-like domains 1.
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the patients were dead or alive at the latest follow-up (P=0.036 
and P=0.007, respectively, χ2 test). The patients who died during 
the follow-up period were older at the time of diagnosis than 
those still alive (P<0.001, Mann-Whitney U test), but the age 
distribution was similar across all categories for the fraction 
of LRIG1-positive cells and all of the intensities (P=0.15 and 
P=0.12, respectively, Kruskal-Wallis test). No other significant 
associations were found between LRIG1 immunoreactivity and 
the clinical parameters. The same analyses were performed 
including only PTC and FTC, since these entities have a more 
favorable clinical course. Both the percentage of positive cells 
and intensity of staining were still associated with whether the 
patients were dead or alive at the latest follow-up (P=0.014 
and P=0.002, respectively, χ2 test). The median follow-up time 
was 86 months for PFS, 96 months for DSS, and 96 months for 
OS. Survival analyses were performed for clinical stage, the 
percentage of LRIG1-positive cells and the intensity of LRIG1 
staining. As expected, the clinical stage was a strong prognostic 
factor for OS, DSS and PFS, both when comparing all of the 
stages and when comparing stages I and II with stages III 
and IV (data not shown). No significant associations were 
found between LRIG1 immunoreactivity and the cumulative 
survival rates in Cohort3-TMA, both when analysing the whole 
cohort as well as when analysing PTC only (n=72). Performing 
additional sub-group analysis for smaller groups was not 
relevant due to the limited size of each group.
Animal experiments. To experimentally address the role of 
LRIG1 in mutated RET-driven MTC, a mouse strain carrying 
a deficient Lrig1 allele was crossed with a transgenic mouse 
strain that expresses human RET2B in thyroid parafol-
licular cells (C-cells) and is known to develop MTC or C-cell 
hyperplasia within 2-years and at high frequencies (13 and 
77%, respectively) (34,35). The resulting offspring that were 
heterozygous for both the Lrig1 and the RET2B alleles were 
crossed with heterozygous Lrig1 mice to yield Lrig1 wild-type, 
heterozygous, or knockout mice with or without the RET2B 
transgene (Fig. 4A). Only mice that were positive for the RET2B 
transgene were included in the study. In total, 125 mice were 
included, of which 46 (37%) were Lrig1 wild-type, 49 (39%) 
were Lrig1 heterozygous, and 30 (24%) were Lrig1-deficient. 
The mice were followed up for up to 2 years. Blood samples 
were obtained and calcitonin levels were measured every 
third month beginning at 6 months of age. Surprisingly, the 
plasma calcitonin levels were below the detection limit of the 
assay in all of the samples that were analyzed, except for four 
samples, which were calcitonin positive and represented three 
different mice. Of the three mice with elevated calcitonin 
Figure 2. LRIG1 expression levels in PTC, MTC, and normal thyroid tissues. (A) Boxplots showing relative LRIG1 mRNA levels in normal thyroid tissue 
(n=58) and PTC (n=502) according to the TCGA dataset. The LRIG1 expression level was significantly lower in PTC than in normal thyroid tissue (P=2.2e-16). 
Outlier values are marked °. (B) Boxplots showing the relative LRIG1 expression in PTC ordered by clinical stage according to the TCGA data set. A higher 
clinical stage was significantly associated with a lower LRIG1 expression (one-way ANOVA, P=0.0035). (C) Boxplots showing the relative LRIG1 mRNA 
expression levels in the normal thyroid gland (n=12) and MTC (n=39) measured with quantitative RT-PCR. Shown are the relative LRIG1/RN18S ratios normal-
ized to the corresponding level in human reference RNA that was arbitrarily set to the value of 1. The relative LRIG1/RN18S ratio was significantly lower in 
MTC than in normal thyroid glands (P=0.00063). Outlier values are marked °. (D) Boxplots showing LRIG1 expression in MTC ordered by clinical stage. A 
higher clinical stage was not significantly associated with a lower LRIG1 expression (Wilcoxon signed-rank test, P=0.136). PTC, papillary thyroid carcinoma; 
MTC, medullary thyroid carcinoma; RET, rearranged during transfection; LRIG1, leucine-rich repeats and immunoglobulin-like domains 1.
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levels, one was Lrig1 wild-type and two were heterozygous 
for the Lrig1 allele. Eleven of the 46 wild-type mice (24%), 
8 of the 49 heterozygous mice (16%), and 7 of the 30 knockout 
mice (23%) died prematurely, that is, before the planned 
termination at 24 months. For most of the prematurely dead 
mice, the cause of death was undetermined; therefore, they 
were excluded from further analysis. At 24 months of age, the 
remaining mice were sacrificed and their thyroid glands were 
collected, formaldehyde-fixed, paraffin embedded, sectioned 
and routinely stained. Pre-invasive lesions were found in 
13 of the 35 wild-type glands (37%), 12 of the 41 heterozy-
gous glands (29%), and in 11 of the 23 Lrig1-deficient glands 
(48%) (Fig. 4B). The remaining 63 thyroid glands showed 
no evidence of pathological changes. The difference in the 
incidence of pre-invasive lesions between the wild-type and 
Lrig1-deficient mice was not statistically significant (P=0.42, 
χ2 test). Furthermore, no overt cancers were observed.
Discussion
In this study, the importance of LRIG1 in thyroid cancer was 
investigated. We showed that LRIG1 physically interacted 
with and inhibited the activation of the MEN-associated and 
thyroid cancer-associated mutant RET receptors RET2A and 
RET2B and was downregulated in human PTC and MTC 
compared to normal thyroid gland tissues. However, in our 
mouse model of RET2B-driven MTC, no significant effect of 
Lrig1 gene ablation was observed.
The interaction between LRIG1 and tyrosine kinase recep-
tors has been described previously for normal RET (27), and 
here we showed similar interactions between LRIG1 and the 
mutated and oncogenic RET variants RET2A and RET2B. 
That is, LRIG1 physically interacted with both RET2A and 
RET2B, as well as inhibited their constitutive activation as 
monitored with receptor tyrosine phosphorylation blots. This 
Figure 4. RET2B-induced thyroid gland lesions in mice. (A) A schematic 
drawing of the mouse experimental set-up. Mice with the genotypes RET2B+/-; 
Lrig1+/- and Lrig1+/- were mated to generate offspring of the genotypes 
RET2B+/-; Lrig1+/+, RET2B+/-; Lrig1+/- and RET2B+/-; Lrig1-/-. The RET2B-/- off-
spring were not included in the study. Beginning at 6 months of age, the blood 
was sampled every 3rd month and the calcitonin levels were determined. At 
24 months of age or at signs of the disease, the mice were sacrificed and their 
thyroid glands were analyzed. A graphic mouse symbol was downloaded from 
http://clipartall.com and modified in Photoshop. (B) A micrograph showing 
an example of a hematoxylin and eosin-stained mouse thyroid gland with 
apre-invasive lesion. Scale bars, 100 µm. Lrig1, leucine-rich repeats and 
immunoglobulin-like domains 1; RET, rearranged during transfection.
Figure 3. Examples of immunohistochemical stainings of LRIG1 in papillary thyroid carcinomas and their respective scores. (A) A tumor with no positive 
LRIG1 staining. (B) A tumor with weak LRIG1 staining intensity (1+) and 1-25% positive cells. (C) A tumor with intermediate LRIG1 staining intensity (2+) 
and 26-50% positive cells. (D) A tumor with intermediate LRIG1 staining intensity (2+) and 76-100% positive cells. Scale bars, 10 µm. LRIG1, leucine-rich 
repeats and immunoglobulin-like domains 1.
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indicates that LRIG1 may play an important role in the initiation 
or progression of thyroid cancer because mutated RET recep-
tors, including RET2A and RET2B, are established drivers of 
the majority of MTCs and of some PTCs. However, the RET 
fusion proteins found in PTC are cytosolic whereas LRIG1 is a 
transmembrane protein, and whether they functionally interact 
was not addressed in the present study. Nevertheless, altered 
signaling pathways in PTC, particularly activation of the MAPK 
signaling pathway, may be the result of other genetic events, 
such as activating mutations in BRAF and RAS genes (reviewed 
in ref. 37). This activation may result in the upregulation of other 
oncogenic proteins, including other targets of LRIG1, such as 
the RTKs EGFR and MET. Thus, LRIG1 could be important in 
PTC through interactions with other proteins as well.
In Cohort1-TCGA, LRIG1 expression data were available 
for 502 PTC cases but not for other thyroid cancer subtypes; 
whereas in Cohort2-MTC, we determined the LRIG1 mRNA 
levels in 39 MTCs. Intriguingly, LRIG1 was downregulated in 
both PTC and MTC compared to normal thyroid gland tissue. 
Because many PTCs have been reported to have a RET rear-
rangement and the majority of MTCs de facto showed a mutated 
RET, the downregulation of LRIG1 expression seen supports the 
notion that LRIG1 downregulation may play a causative role in 
the etiologies of PTC and MTC. However, as discussed above, 
this study does not provide evidence for a functional interaction 
between LRIG1 and the RET fusion proteins found in PTC; 
however, LRIG1 may possibly exert effects through interactions 
with other RTKs as well. Another important point is that the 
use of normal thyroid tissue as control for MTC may not be 
optimal, but microdissection of parafollicular cells for control 
was unfortunately not possible to obtain from this material. The 
IHC analysis of Cohort3-TMA revealed no association between 
LRIG1 immunoreactivity and patient survival. However, known 
prognostic factors, such as clinical stage and histological type, 
were confirmed to be predictive of patient survival in this cohort. 
Because the majority of cases in Cohort3-TMA (72/119) and all 
of the cases in Cohort1-TCGA were of the PTC subtype, the data 
indicate that neither the LRIG1 protein nor the LRIG1 mRNA is 
prognostic in PTC. Although it could be argued that the material 
used for the IHC analysis was rather small (118 cases, in total), 
previous studies of similarly sized cohorts have shown signifi-
cant associations between LRIG immunoreactivity and patient 
survival for other types of cancer (16,17,19,21,38-41). Therefore, 
the importance of the LRIG1 protein and RNA expression levels 
as prognostic markers in PTC may be of less interest for further 
study. Because of the relative rarity of MTC, only 5 of the 111 
evaluated patients in Cohort3-TMA represented MTC cases, it 
was not possible to address the role of LRIG1 immunoreactivity 
as a prognostic marker in MTC in this material. However, since 
LRIG1 mRNA was downregulated in MTC, it may be of interest 
to investigate the prognostic value of LRIG1 immunoreactivity 
in a larger MTC cohort.
The deletion of Lrig1 did not affect the apparent tumor inci-
dence or malignancy grade in the mouse model of RET2B-driven 
MTC. Our hypothesis was that Lrig1, through its suppression 
of RET2B, would serve as a tumor suppressor in this model 
system and, therefore, its deletion would enhance the incidence, 
progression, or severity of the disease. However, no such MTC 
promoting effects were observed in the Lrig1-deficient mice. 
One possible explanation for the lack of apparent effects of 
Lrig1 ablation could be that Lrig1 expression in the wild-type 
tumors was downregulated through tumor-intrinsic mechanisms, 
thereby obviating the need for and masking the effects of genetic 
ablation. This hypothesis is consistent with the strong down-
regulation of LRIG1 expression that was seen in the human MTC 
series. Regrettably, we were unable to determine whether Lrig1 
expression was actually downregulated in the mouse tumors 
because the Lrig1 expression levels could not be determined in 
the pre-invasive lesions in a reliable manner. Relatively, many of 
the mice (24%) died or had to be sacrificed before the planned 
Table I. Clinical features of the patients in Cohort3-TMA.
Clinical features No. of cases
TNM stage
  I 53
  II 11
  III 27
  IV 27
Histology
  PTC 72
  FTC 18
  MTC 5
  ATC 8
  PDTC 4
  FTC-oncocytic type  12
Deceased
  Yes 65
  No 60
Deceased due to thyroid cancer
  Yes 25
  No 100
Relapse
  Yes 37
  No 88
Intensity of LRIG1 staining
  Absent 28
  Weak 72
  Moderate 18
  Intense 0
Percentage of LRIG1-positive cells
  None 28
  1-25% 18
  26-50% 17
  51-75% 25
  76-100% 30
Sex
  Male 40
  Female 85
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; 
MTC, medullary thyroid carcinoma; PDTC, poorly differentiated 
thyroid carcinoma; ACT, anaplastic thyroid carcinoma; LRIG1, leu-
cine-rich repeats and immunoglobulin-like domains 1.
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termination at 24 months of age. In most of these cases, the cause 
of premature death was undetermined. We do not know if the 
RET2B transgene caused an increased mortality rate among the 
experimental mice because no RET2B-negative control colonies 
were maintained in parallel with the RET2B transgenic experi-
mental group. However, the cause of premature deaths is not 
likely to have been MTC because the plasma calcitonin levels 
were analyzed every third month and none of the prematurely 
dead mice showed increased plasma calcitonin levels prior to 
their death. In fact, detectable plasma calcitonin levels were 
observed in only 3 of the 99 (3%) mice. This is in contrast with 
a previous study, in which up to 90% of the RET2B-positive 
mice showed detectable plasma calcitonin levels by the age of 
24 months (35). The reason for the observed difference in MTC 
incidence between the present study and the previous study is not 
known, but it could possibly be due to differences in the calcitonin 
assay-sensitivity due to different amounts of plasma available, 
animal housing conditions, or mouse strain differences. In both 
studies, the genetic backgrounds of the mice were mixed and 
thus, presumably not identical. Nevertheless, pre-invasive thyroid 
gland lesions were found in 37% of wild-type mice and in 48% 
of Lrig1-deficient mice. However, the slightly higher incidence 
of pre-invasive lesions among the Lrig1-deficient mice was not 
statistically significant. Thus, no effect of Lrig1-ablation could 
be demonstrated in our mouse model of RET2B-driven MTC.
In conclusion, our demonstration that LRIG1 negatively 
regulated the thyroid oncoproteins RET2A and RET2B and 
was also downregulated in PTC and MTC suggests that 
LRIG1 plays important roles in thyroid cancer. We believe 
that the possibility that the downregulation of LRIG1 is a 
critical tumor-promoting event during papillary and medul-
lary thyroid carcinogenesis and that LRIG1-based therapies 
could be effective in PTC, MTC and/or other RET-driven 
cancers warrant further investigations. The concept of possible 
LRIG1-based therapies has been described in detail in a recent 
review, highlighting its possible role as a therapeutic inhibitor 
of receptor tyrosine kinase signaling (42). Further studies 
based on our findings may initially include cellular and animal 
studies testing the therapeutic potential of LRIG1 in cellular 
and animal models of PTC and MTC.
Acknowledgements
We would like to thank Sjors Fens, Yvonne Jonsson, Annika 
Holmberg, Charlotte Nordström, and Helena Hermelin for 
their technical help.
Funding
This study was supported by grants from the Swedish Society 
for Medical Research, the Swedish Cancer Society, the Cancer 
Research Foundation in Northern Sweden, the F Olaison 
Foundation, and through the regional agreement between 
Umeå University and Västerbotten County Council in coop-
eration in the fields of medicine, odontology and health.
Availability of data and materials
The materials included in the manuscript, including all rele-
vant raw data, will be made freely available to any researchers 
who wish to use them for non-commercial purposes, while 
preserving necessary confidentiality and anonymity.
Authors' contributions
DL, HH and RH coordinated the data collection, were respon-
sible for the animal experiments, the collection of clinical data 
for cohort 3, carried out the statistical analyses, drafted the 
manuscript, and provided final approval for the submission. 
FCA and GP performed the cellular experiments, critically 
revised the manuscript, and provided final approval for the 
submission. CH collected the data for cohort 1, critically 
revised the manuscript, and provided final approval for the 
submission. CL and NW collected the data for cohort 2, 
critically revised the manuscript, and provided final approval 
for the submission. JH performed all cacitonin analyses and 
interpreted the data of these results, critically revised the 
manuscript, and provided final approval for the submission. 
MT and TT are senior pathologists and conducted the immu-
nohistochemidal evaluations, critically revised the manuscript, 
and provided final approval for the submission.
Ethics approval and consent to participate
The study was approved by the Regional Ethics Review Board 
in Uppsala (dnr 2010/351). Only patients who provided written 
informed consent were included in the study.
Consent for publication
Publication of the clinical datasets in this study does not 
compromise anonymity or confidentiality or breach local data 
protection laws.
Competing interests
The authors declare that they have no competing interests.
References
 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: 
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 
2008. Int J Cancer 127: 2893-2917, 2010. 
 2. DeLellis R and Williams ED: Tumours of the thyroid and parathyroid. 
In: World Health Organization Classification of Tumours. Pathology 
and Genetics of Tumours of Endocrine Organs. DeLellis R and 
Williams ED (eds). Vol. 8. IARC Press, pp51-56, 2004.
 3. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, 
Moretti S, Nicolosi ML, Giani C, Cirello V, et al: Modifications 
in the papillary thyroid cancer gene profile over the last 15 years. 
J Clin Endocrinol Metab 97: E1758-E1765, 2012. 
 4. Romei C, Ciampi R and Elisei R: A comprehensive overview of 
the role of the RET proto-oncogene in thyroid carcinoma. Nat 
Rev Endocrinol 12: 192-202, 2016. 
 5. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, 
Hoff AO, Sherman SI, Lee JE and Evans DB: RET proto-oncogene: 
A review and update of genotype-phenotype correlations in 
hereditary medullary thyroid cancer and associated endocrine 
tumors. Thyroid 15: 531-544, 2005. 
 6. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H and 
Fagin JA: Distinct pattern of ret oncogene rearrangements in 
morphological variants of radiation-induced and sporadic thyroid 
papillary carcinomas in children. Cancer Res 57: 1690-1694, 1997.
 7. Agrawal N AR, Aksoy BA, Ally A, Arachchi H, Asa SL, 
Auman JT, Balasundaram M, Balu S, Baylin SB, Behera M, 
et al: Integrated genomic characterization of papillary thyroid 
carcinoma. Cell 159: 676-690, 2014.
INTERNATIONAL JOURNAL OF ONCOLOGY  52:  1189-1197,  2018 1197
 8. Network CGAR; Cancer Genome Atlas Research Network: 
Integrated genomic characterization of papillary thyroid 
carcinoma. Cell 159: 676-690, 2014. 
 9. Guo D, Holmlund C, Henriksson R and Hedman H: The LRIG 
gene family has three vertebrate paralogs widely expressed 
in human and mouse tissues and a homolog in Ascidiacea. 
Genomics 84: 157-165, 2004. 
10. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, 
Henriksson R and Hedman H: Characterization and tissue-
specific expression of human LRIG2. Gene 332: 35-43, 2004. 
11. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R 
and Hedman H: Cloning, characterization, and expression of 
human LIG1. Biochem Biophys Res Commun 284: 1155-1161, 
2001. 
12. Wang Y, Poulin EJ and Coffey RJ: LRIG1 is a triple threat: 
ERBB negative regulator, intestinal stem cell marker and tumour 
suppressor. Br J Cancer 108: 1765-1770, 2013. 
13. Lindquist D, Kvarnbrink S, Henriksson R and Hedman H: LRIG 
and cancer prognosis. Acta Oncol 53: 1135-1142, 2014. 
14. Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, 
Kotelawala L, Qi L, Griffith OL, Gray JW, et al: Lrig1 is an 
estrogen-regulated growth suppressor and correlates with longer 
relapse-free survival in ERα-positive breast cancer. Mol Cancer 
Res 9: 1406-1417, 2011. 
15. Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, 
Sikic BI and Leyland-Jones B: Single Gene Prognostic 
Biomarkers in Ovarian Cancer: A Meta-Analysis. PLoS One 11: 
e0149183, 2016. 
16. Lindström AK, Ekman K, Stendahl U, Tot T, Henriksson R, 
Hedman H and Hellberg D: LRIG1 and squamous epithelial 
uterine cervical cancer: Correlation to prognosis, other tumor 
markers, sex steroid hormones, and smoking. Int J Gynecol 
Cancer 18: 312-317, 2008. 
17. Tanemura A, Nagasawa T, Inui S and Itami S: LRIG-1 provides 
a novel prognostic predictor in squamous cell carcinoma of the 
skin: Immunohistochemical analysis for 38 cases. Dermatol 
Surg 31: 423-430, 2005. 
18. Lindquist D, Näsman A, Tarján M, Henriksson R, Tot T, 
Dalianis T and Hedman H: Expression of LRIG1 is associated 
with good prognosis and human papillomavirus status in oropha-
ryngeal cancer. Br J Cancer 110: 1793-1800, 2014. 
19. Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT, Lee SC, Cheng J, 
Chen CM, Chan C, Chao SC, et al: LRIG1 modulates 
aggressiveness of head and neck cancers by regulating EGFR-
MAPK-SPHK1 signaling and extracellular matrix remodeling. 
Oncogene 33: 1375-1384, 2014. 
20. Kvarnbrink S, Karlsson T, Edlund K, Botling J, Lindquist D, 
Jirström K, Micke P, Henriksson R, Johansson M and Hedman H: 
LRIG1 is a prognostic biomarker in non-small cell lung cancer. 
Acta Oncol 54: 1113-1119, 2015. 
21. Yang B, Dai C, Tan R, Zhang B, Meng X, Ye J, Wang X, Wei L, 
He F and Chen Z: Lrig1 is a positive prognostic marker in hepa-
tocellular carcinoma. Onco Targets Ther 9: 7071-7079, 2016. 
22. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, 
Henriksson R, Rechavi G, Hedman H, et al: LRIG1 restricts 
growth factor signaling by enhancing receptor ubiquitylation and 
degradation. EMBO J 23: 3270-3281, 2004. 
23. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, 
Carraway KL III and Sweeney C: The leucine-rich repeat protein 
LRIG1 is a negative regulator of ErbB family receptor tyrosine 
kinases. J Biol Chem 279: 47050-47056, 2004. 
24. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, 
Young LJ, Cardiff RD, Carraway KL III and Sweeney C: 
Suppression of the negative regulator LRIG1 contributes to ErbB2 
overexpression in breast cancer. Cancer Res 68: 8286-8294, 2008. 
25. Stutz MA, Shattuck DL, Laederich MB, Carraway KL III and 
Sweeney C: LRIG1 negatively regulates the oncogenic EGF 
receptor mutant EGFRvIII. Oncogene 27: 5741-5752, 2008. 
26. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, 
Carraway KL III and Sweeney C: LRIG1 is a novel negative 
regulator of the Met receptor and opposes Met and Her2 synergy. 
Mol Cell Biol 27: 1934-1946, 2007. 
27. Ledda F, Bieraugel O, Fard SS, Vilar M and Paratcha G: Lrig1 
is an endogenous inhibitor of Ret receptor tyrosine kinase acti-
vation, downstream signaling, and biological responses to GDNF. 
J Neurosci 28: 39-49, 2008. 
28. Rondahl V, Holmlund C, Karlsson T, Wang B, Faraz M, 
Henriksson R and Hedman H: Lrig2-deficient mice are protected 
against PDGFB-induced glioma. PLoS One 8: e73635, 2013. 
29. Alsina FC, Hita FJ, Fontanet PA, Irala D, Hedman H, Ledda F 
and Paratcha G: Lrig1 is a cell-intrinsic modulator of hippo-
campal dendrite complexity and BDNF signaling. EMBO 
Rep 17: 601-616, 2016. 
30. Nilsson J, Starefeldt A, Henriksson R and Hedman H: LRIG1 
protein in human cells and tissues. Cell Tissue Res 312: 65-71, 2003.
31. Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, 
Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL, 
Rudkin BB, et al: Distinct biological properties of two RET 
isoforms activated by MEN 2A and MEN 2B mutations. 
Oncogene 14: 265-275, 1997. 
32. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, 
Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al: 
Activation of RET as a dominant transforming gene by germline 
mutations of MEN2A and MEN2B. Science 267: 381-383, 1995. 
33. Wang N, Kjellin H, Sofiadis A, Fotouhi O, Juhlin CC, 
Bäckdahl M, Zedenius J, Xu D, Lehtiö J and Larsson C: Genetic 
and epigenetic background and protein expression profiles in 
relation to telomerase activation in medullary thyroid carcinoma. 
Oncotarget 7: 21332-21346, 2016.
34. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, 
Sano S, Ozawa K, Inui S, Nakata A, Takagi T, et al: Targeted 
disruption of LIG-1 gene results in psoriasiform epidermal 
hyperplasia. FEBS Lett 521: 67-71, 2002. 
35. Acton DS, Velthuyzen D, Lips CJ and Höppener JW: Multiple 
endocrine neoplasia type 2B mutation in human RET oncogene 
induces medullary thyroid carcinoma in transgenic mice. 
Oncogene 19: 3121-3125, 2000. 
36. van Veelen W, van Gasteren CJ, Acton DS, Franklin DS, Berger R, 
Lips CJ and Höppener JW: Synergistic effect of oncogenic RET 
and loss of p18 on medullary thyroid carcinoma development. 
Cancer Res 68: 1329-1337, 2008. 
37. Xing M: Molecular pathogenesis and mechanisms of thyroid 
cancer. Nat Rev Cancer 13: 184-199, 2013. 
38. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, 
Hedman H and Henriksson R: Perinuclear leucine-rich repeats 
and immunoglobulin-like domain proteins (LRIG1-3) as prog-
nostic indicators in astrocytic tumors. Acta Neuropathol 111: 
238-246, 2006. 
39. Hedman H, Lindström AK, Tot T, Stendahl U, Henriksson R and 
Hellberg D: LRIG2 in contrast to LRIG1 predicts poor survival 
in early-stage squamous cell carcinoma of the uterine cervix. 
Acta Oncol 49: 812-815, 2010. 
40. Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, 
Bragge H, Henriksson R and Hedman H: Cytoplasmic LRIG2 
expression is associated with poor oligodendroglioma patient 
survival. Neuropathology 29: 242-247, 2009. 
41. Muller S, Lindquist D, Kanter L, Flores-Staino C, Henriksson R, 
Hedman H and Andersson S: Expression of LRIG1 and LRIG3 
correlates with human papillomavirus status and patient survival 
in cervical adenocarcinoma. Int J Oncol 42: 247-252, 2013. 
42. Neirinckx V, Hedman H and Niclou SP: Harnessing LRIG1-
mediated inhibition of receptor tyrosine kinases for cancer 
therapy. Biochim Biophys Acta 1868: 109-116, 2017.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International (CC BY-NC-ND 4.0) License.
